A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers
The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus gro...
Gespeichert in:
| Veröffentlicht in: | Alzheimer disease and associated disorders 2001-04, Vol.15 (2), p.80-88 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 88 |
|---|---|
| container_issue | 2 |
| container_start_page | 80 |
| container_title | Alzheimer disease and associated disorders |
| container_volume | 15 |
| creator | POST, Stephen G STUCKEY, Jon C WHITEHOUSE, Peter J OLLERTON, Sally DURKIN, Casey ROBBINS, Dorothy FALLCREEK, Stephanie J |
| description | The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus groups on the experience of treatment. These groups engaged both Alzheimer disease-affected persons, their caregivers, and a multidisciplinary professional core. We conclude that therapeutic goals need to be better addressed with patients and families, as well as better monitored, with the possibility of withdrawing therapy as appropriate. We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy. |
| doi_str_mv | 10.1097/00002093-200104000-00007 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00002093_200104000_00007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11391089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-207820e0bd0498ab078c3fdf551bd6e4535959cd892769d64a71d40fb3e132123</originalsourceid><addsrcrecordid>eNpNkMtOAyEUhonR2Fp9BcPC7ehhgLm4a-o1aeJG1xOGS4tpmQmnTaNPL2PrhQ3h5_8O4SOEMrhmUJc3kFYONc9yAAYinbIhKo_ImElRZILJ4piMoUoV4IKNyBni-9DgEk7JiDFes3Q7JrspdZ3eIl3EbtvTLlDdLYLf-C5kNixV0D4s6Noar9UQIvWBTlefS-vXNlLj0Sq09JbeeexVTKBF2trNztpA-9g5i5gwtUKqgknDA24TiOfkxKXQXhz2CXl7uH-dPWXzl8fn2XSeaS5gk_5XVjlYaA2IulJtOmrujJOStaawQnJZy1qbqs7LojaFUCUzAlzLLeM5y_mEVPu5OnaI0bqmj36t4kfDoBlcNj8um1-X31GZ0Ms92m_bJOAPPMhLhatDQaFWKxcHW_jvAWBVzvgXr_19Jw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>POST, Stephen G ; STUCKEY, Jon C ; WHITEHOUSE, Peter J ; OLLERTON, Sally ; DURKIN, Casey ; ROBBINS, Dorothy ; FALLCREEK, Stephanie J</creator><creatorcontrib>POST, Stephen G ; STUCKEY, Jon C ; WHITEHOUSE, Peter J ; OLLERTON, Sally ; DURKIN, Casey ; ROBBINS, Dorothy ; FALLCREEK, Stephanie J</creatorcontrib><description>The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus groups on the experience of treatment. These groups engaged both Alzheimer disease-affected persons, their caregivers, and a multidisciplinary professional core. We conclude that therapeutic goals need to be better addressed with patients and families, as well as better monitored, with the possibility of withdrawing therapy as appropriate. We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy.</description><identifier>ISSN: 0893-0341</identifier><identifier>EISSN: 1546-4156</identifier><identifier>DOI: 10.1097/00002093-200104000-00007</identifier><identifier>PMID: 11391089</identifier><identifier>CODEN: ADADE2</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Alzheimer Disease - drug therapy ; Alzheimer Disease - psychology ; Attitude of Health Personnel ; Biological and medical sciences ; Cholinergic system ; Cognition Disorders - drug therapy ; Cognition Disorders - psychology ; Focus Groups ; Humans ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Nootropic Agents - adverse effects ; Nootropic Agents - therapeutic use ; Pharmacology. Drug treatments ; Pilot Projects ; Quality of Life</subject><ispartof>Alzheimer disease and associated disorders, 2001-04, Vol.15 (2), p.80-88</ispartof><rights>2001 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-207820e0bd0498ab078c3fdf551bd6e4535959cd892769d64a71d40fb3e132123</citedby><cites>FETCH-LOGICAL-c340t-207820e0bd0498ab078c3fdf551bd6e4535959cd892769d64a71d40fb3e132123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1001821$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11391089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POST, Stephen G</creatorcontrib><creatorcontrib>STUCKEY, Jon C</creatorcontrib><creatorcontrib>WHITEHOUSE, Peter J</creatorcontrib><creatorcontrib>OLLERTON, Sally</creatorcontrib><creatorcontrib>DURKIN, Casey</creatorcontrib><creatorcontrib>ROBBINS, Dorothy</creatorcontrib><creatorcontrib>FALLCREEK, Stephanie J</creatorcontrib><title>A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers</title><title>Alzheimer disease and associated disorders</title><addtitle>Alzheimer Dis Assoc Disord</addtitle><description>The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus groups on the experience of treatment. These groups engaged both Alzheimer disease-affected persons, their caregivers, and a multidisciplinary professional core. We conclude that therapeutic goals need to be better addressed with patients and families, as well as better monitored, with the possibility of withdrawing therapy as appropriate. We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy.</description><subject>Aged</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - psychology</subject><subject>Attitude of Health Personnel</subject><subject>Biological and medical sciences</subject><subject>Cholinergic system</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - psychology</subject><subject>Focus Groups</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nootropic Agents - adverse effects</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Quality of Life</subject><issn>0893-0341</issn><issn>1546-4156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtOAyEUhonR2Fp9BcPC7ehhgLm4a-o1aeJG1xOGS4tpmQmnTaNPL2PrhQ3h5_8O4SOEMrhmUJc3kFYONc9yAAYinbIhKo_ImElRZILJ4piMoUoV4IKNyBni-9DgEk7JiDFes3Q7JrspdZ3eIl3EbtvTLlDdLYLf-C5kNixV0D4s6Noar9UQIvWBTlefS-vXNlLj0Sq09JbeeexVTKBF2trNztpA-9g5i5gwtUKqgknDA24TiOfkxKXQXhz2CXl7uH-dPWXzl8fn2XSeaS5gk_5XVjlYaA2IulJtOmrujJOStaawQnJZy1qbqs7LojaFUCUzAlzLLeM5y_mEVPu5OnaI0bqmj36t4kfDoBlcNj8um1-X31GZ0Ms92m_bJOAPPMhLhatDQaFWKxcHW_jvAWBVzvgXr_19Jw</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>POST, Stephen G</creator><creator>STUCKEY, Jon C</creator><creator>WHITEHOUSE, Peter J</creator><creator>OLLERTON, Sally</creator><creator>DURKIN, Casey</creator><creator>ROBBINS, Dorothy</creator><creator>FALLCREEK, Stephanie J</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20010401</creationdate><title>A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers</title><author>POST, Stephen G ; STUCKEY, Jon C ; WHITEHOUSE, Peter J ; OLLERTON, Sally ; DURKIN, Casey ; ROBBINS, Dorothy ; FALLCREEK, Stephanie J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-207820e0bd0498ab078c3fdf551bd6e4535959cd892769d64a71d40fb3e132123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Aged</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - psychology</topic><topic>Attitude of Health Personnel</topic><topic>Biological and medical sciences</topic><topic>Cholinergic system</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - psychology</topic><topic>Focus Groups</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nootropic Agents - adverse effects</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Quality of Life</topic><toplevel>online_resources</toplevel><creatorcontrib>POST, Stephen G</creatorcontrib><creatorcontrib>STUCKEY, Jon C</creatorcontrib><creatorcontrib>WHITEHOUSE, Peter J</creatorcontrib><creatorcontrib>OLLERTON, Sally</creatorcontrib><creatorcontrib>DURKIN, Casey</creatorcontrib><creatorcontrib>ROBBINS, Dorothy</creatorcontrib><creatorcontrib>FALLCREEK, Stephanie J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Alzheimer disease and associated disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POST, Stephen G</au><au>STUCKEY, Jon C</au><au>WHITEHOUSE, Peter J</au><au>OLLERTON, Sally</au><au>DURKIN, Casey</au><au>ROBBINS, Dorothy</au><au>FALLCREEK, Stephanie J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers</atitle><jtitle>Alzheimer disease and associated disorders</jtitle><addtitle>Alzheimer Dis Assoc Disord</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>15</volume><issue>2</issue><spage>80</spage><epage>88</epage><pages>80-88</pages><issn>0893-0341</issn><eissn>1546-4156</eissn><coden>ADADE2</coden><abstract>The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus groups on the experience of treatment. These groups engaged both Alzheimer disease-affected persons, their caregivers, and a multidisciplinary professional core. We conclude that therapeutic goals need to be better addressed with patients and families, as well as better monitored, with the possibility of withdrawing therapy as appropriate. We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11391089</pmid><doi>10.1097/00002093-200104000-00007</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-0341 |
| ispartof | Alzheimer disease and associated disorders, 2001-04, Vol.15 (2), p.80-88 |
| issn | 0893-0341 1546-4156 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00002093_200104000_00007 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aged Alzheimer Disease - drug therapy Alzheimer Disease - psychology Attitude of Health Personnel Biological and medical sciences Cholinergic system Cognition Disorders - drug therapy Cognition Disorders - psychology Focus Groups Humans Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Nootropic Agents - adverse effects Nootropic Agents - therapeutic use Pharmacology. Drug treatments Pilot Projects Quality of Life |
| title | A focus group on cognition-enhancing medications in Alzheimer disease : Disparities between professionals and consumers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A00%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20focus%20group%20on%20cognition-enhancing%20medications%20in%20Alzheimer%20disease%20:%20Disparities%20between%20professionals%20and%20consumers&rft.jtitle=Alzheimer%20disease%20and%20associated%20disorders&rft.au=POST,%20Stephen%20G&rft.date=2001-04-01&rft.volume=15&rft.issue=2&rft.spage=80&rft.epage=88&rft.pages=80-88&rft.issn=0893-0341&rft.eissn=1546-4156&rft.coden=ADADE2&rft_id=info:doi/10.1097/00002093-200104000-00007&rft_dat=%3Cpubmed_cross%3E11391089%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11391089&rfr_iscdi=true |